BIOMAT Database Logo BIOMAT Database Logo

Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. 1996

S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada.

We determined changes in blood pressure, cardiac output, and total peripheral conductance evoked by intravenous infusions of angiotensin II (Ang II) in conscious, unrestrained normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) before and after pretreatment with bosentan, a nonselective endothelin antagonist. Blood pressure was recorded by radiotelemetry and cardiac output by ultrasonic transit-time flow probes. Bosentan per se failed to affect basal blood pressure and evoked only small changes in cardiac output and total peripheral conductance in both strains. The pressor effects of Ang II were exaggerated in SHR compared with WKY. Strikingly, bosentan pretreatment blunted the increases in blood pressure, the fall in cardiac output, and the decreases in conductance evoked by lower doses of Ang II but not higher doses of the peptide. This effect was observed in both rat strains but was more pronounced in SHR. These data suggest that endothelin contributes to the hemodynamic effects of Ang II in both SHR and WKY and that endothelin may contribute to the exaggerated pressor responsiveness of SHR to Ang II.

UI MeSH Term Description Entries
D008297 Male Males
D011311 Pressoreceptors Receptors in the vascular system, particularly the aorta and carotid sinus, which are sensitive to stretch of the vessel walls. Baroreceptors,Receptors, Stretch, Arterial,Receptors, Stretch, Vascular,Stretch Receptors, Arterial,Stretch Receptors, Vascular,Arterial Stretch Receptor,Arterial Stretch Receptors,Baroreceptor,Pressoreceptor,Receptor, Arterial Stretch,Receptor, Vascular Stretch,Receptors, Arterial Stretch,Receptors, Vascular Stretch,Stretch Receptor, Arterial,Stretch Receptor, Vascular,Vascular Stretch Receptor,Vascular Stretch Receptors
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000077300 Bosentan A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS. 4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide,Bosentan Anhydrous,Bosentan Monohydrate,Ro 47-0203,Ro-47-0203,Tracleer,Ro 47 0203,Ro 470203
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan.
November 2000, Hypertension (Dallas, Tex. : 1979),
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Effect of angiotensin II receptor antagonist and endothelin receptor antagonist on nitroglycerin tolerance in rats.
June 2001, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril.
June 1991, Hypertension (Dallas, Tex. : 1979),
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1.
November 2000, Journal of cardiovascular pharmacology,
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
August 1997, Hypertension (Dallas, Tex. : 1979),
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension.
December 2001, American journal of physiology. Heart and circulatory physiology,
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Effect of an angiotensin antagonist, Sar1-Ala8-angiotensin II on physiological thirst.
March 1976, Pharmacology, biochemistry, and behavior,
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly.
August 1980, The Journal of clinical endocrinology and metabolism,
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Hemodynamic effects of an angiotensin II antagonist in rabbits with perinephritis hypertension.
June 1977, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
S M Balakrishnan, and H D Wang, and V Gopalakrishnan, and T W Wilson, and J R McNeill
Effect of intraventricular infusion of an angiotensin II antagonist on 125I-angiotensin II binding in rats.
January 1986, European journal of pharmacology,
Copied contents to your clipboard!